Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Badesch

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Chest|July 16, 2008
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survivalRaymond L Benza, Robyn J Barst, Nazzareno Galie, et al.
Cardiovascular Therapeutics|September 3, 2011
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertensionDavid B Badesch, Jeremy Feldman, Anne Keogh, et al.
Respiratory Medicine|May 1, 2009
Pulmonary function testing in patients with pulmonary arterial hypertensionZhi-Cheng Jing, Xi-Qi Xu, David B Badesch, et al.
Chest|May 26, 2012
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trialVictor F Tapson, Fernando Torres, Fiona Kermeen, et al.
Journal of the American Heart Association|April 27, 2022
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association RegistryKevin Y Chang, Sue Duval, David B Badesch, et al.
Annals of Internal Medicine|October 22, 2008
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trialGérald Simonneau, Lewis J Rubin, Nazzareno Galiè, et al.
Chest|July 8, 2019
ResponseJames R Klinger, Gregory Elliott, Deborah J Levine, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Clinical risk factors for portopulmonary hypertensionSteven M Kawut, Michael J Krowka, James F Trotter, et al.
Chest|June 13, 2015
Five-Year outcomes of patients enrolled in the REVEAL RegistryHarrison W Farber, Dave P Miller, Abby D Poms, et al.
Chest|January 15, 2009
Serotonin transporter polymorphisms in patients with portopulmonary hypertensionKari E Roberts, Michael B Fallon, Michael J Krowka, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Chest|July 16, 2008
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survivalRaymond L Benza, Robyn J Barst, Nazzareno Galie, et al.
Cardiovascular Therapeutics|September 3, 2011
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertensionDavid B Badesch, Jeremy Feldman, Anne Keogh, et al.
Respiratory Medicine|May 1, 2009
Pulmonary function testing in patients with pulmonary arterial hypertensionZhi-Cheng Jing, Xi-Qi Xu, David B Badesch, et al.
Chest|May 26, 2012
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trialVictor F Tapson, Fernando Torres, Fiona Kermeen, et al.
Journal of the American Heart Association|April 27, 2022
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association RegistryKevin Y Chang, Sue Duval, David B Badesch, et al.
Annals of Internal Medicine|October 22, 2008
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trialGérald Simonneau, Lewis J Rubin, Nazzareno Galiè, et al.
Chest|July 8, 2019
ResponseJames R Klinger, Gregory Elliott, Deborah J Levine, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Clinical risk factors for portopulmonary hypertensionSteven M Kawut, Michael J Krowka, James F Trotter, et al.
Chest|June 13, 2015
Five-Year outcomes of patients enrolled in the REVEAL RegistryHarrison W Farber, Dave P Miller, Abby D Poms, et al.
Chest|January 15, 2009
Serotonin transporter polymorphisms in patients with portopulmonary hypertensionKari E Roberts, Michael B Fallon, Michael J Krowka, et al.
Pageof 9